中文摘要：

为存在药品发现新应用，当药重新定位，知道，是为解决高开销的问题的验证策略但是在药发现的低生产率。当前，为药重新定位的流行计算方法基于他们的特征主要集中于已知的药的类似或关联，包括化学结构，副作用，基因表示侧面，或化学蛋白质的 interactome。然而，如此的面向药的方法可以抑制最新预言的功能到药理学存在的药的功能的空间。临床上，许多药被发现了绑离开目标(即到除他们的主要目标以外的受体) ，它能导致不受欢迎的效果。在这研究，它集成已知的药目标信息，我们为基于他们的小径侧面评估在药和疾病之间的关系建议面向疾病的策略。这个方法的基本假设是施加治疗学的效果的药不能仅仅直接指向疾病相关的蛋白质而且调制涉及病理学的过程的小径。在在 2010 测试八全球畅销的药之上(有超过三个目标的各个) ，食物及药品管理局(食物药品管理局，美国) 各个的同意的治疗学的功能在顶被包括 10 个预言的指示。平均，用我们的方法做的 60% 预言的结果被文学证明。这条途径能被用来补充存在方法并且可以在药重新定位和副作用评估提供一个新观点。

英文摘要：

Finding new applications for existing pharmaceuticals, known as drug repositioning, is a validated strategy for resolving the problem of high expenditure but low productivity in drug discovery. Currently, the prevalent computational methods for drug repositioning are focused mainly on the similarity or relevance between known drugs based on their ＂features＂, including chemical structure, side effects, gene expression profile, and/or chemical-protein interactome. However, such drug-oriented methods may constrain the newly predicted functions to the pharmacological functional space of the existing drugs. Clinically, many drugs have been found to bind ＂off-target＂ （i.e. to receptors other than their primary targets）, which can lead to undesirable effects. In this study, which integrates known drug target information, we propose a disease-oriented strategy for evaluating the relationship between drugs and disease based on their pathway profile. The basic hypothesis of this method is that drugs exerting a therapeutic effect may not only directly target the disease-related proteins but also modulate the pathways involved in the pathological process. Upon testing eight of the global best-selling drugs in 2010 （each with more than three targets）, the FDA （Food and Drug Administration, USA）-approved therapeutic function of each was included in the top 10 predicted indications. On average, 60% of predicted results made using our method are proved by literature. This approach could be used to complement existing methods and may provide a new perspective in drug repositioning and side effect evaluation.